Advertisement

Current Gastroenterology Reports

, Volume 7, Issue 1, pp 63–70 | Cite as

Complementary and alternative medicine in the treatment of chronic liver disease

  • Robert G. Batey
  • Ses J. Salmond
  • Alan Bensoussan
Article

Abstract

Interest in and use of complementary and alternative medicines (CAM) in the treatment of chronic liver diseases has increased in the past decade. However, this has not been supported by a significant increase in sound clinical research evidence for their efficacy. The research literature is growing, providing improved knowledge on population use of CAM, possible mechanisms of action of a large range of complementary and alternative medications, and possible specific indications for these agents in patients with liver disease. Although curative potential for CAM has not been documented consistently in any liver disorder, it is possible to identify anti-inflammatory activity and cytoprotective capacity for a number of agents from different branches of the world of CAM. Evidence grows for potential harm from an increasing number of compounds. Concurrently, clarity is increasing in relation to which specific constituents cause the harm and the mechanisms by which damage is produced.

Keywords

Chronic Liver Disease Silymarin Silibinin Glycyrrhizin Pyrrolizidine Alkaloid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    MacLennan AH, Wilson DH, Taylor AW: The escalating costs and prevalence of alternative medicine. Prevent Med 2002, 35:166–173.CrossRefGoogle Scholar
  2. 2.
    Eisenberg DM, Kessler RD, Van Rompay MI, et al.: Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 2001, 135:344–351.PubMedGoogle Scholar
  3. 3.
    Fogden E, Neuberger J: Alternative medicines and the liver. Liver Int 2003, 23:213–220. This review is of value because it summarizes the extent of use of CAM in liver clinic patients, examines the utility of a number of commonly used agents, and discusses safety aspects of CAM usage. The authors conclude that data are insufficient to allow any recommendations for use of CAM in liver disease at present.PubMedCrossRefGoogle Scholar
  4. 4.
    Complementary Medicines, UK [market report]. London: Mintel International Group; 2003.Google Scholar
  5. 5.
    Seeff LB, Lindsay KL, Bacon BR, et al.: Complementary and alternative medicine in chronic liver disease. Hepatology 2001, 34:595–603.PubMedCrossRefGoogle Scholar
  6. 6.
    McCulloch M, Broffman M, Gao J, Colford JM Jr: Chinese herbal medicine and interferon in the treatment of chronic hepatitis B: a meta-analysis of randomized, controlled trials. Am J Public Health 2002, 92:1619–1627.PubMedCrossRefGoogle Scholar
  7. 7.
    Coon JT, Ernst E: Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review. J Hepatol 2004, 40:491–500.PubMedCrossRefGoogle Scholar
  8. 8.
    Batey RG, Cao Q: CH100, a Chinese herbal preparation, protects against Con A mediated hepatitis in alcohol consuming rats. Alcoholism Clin Exp Res 2000, 62:381–385.Google Scholar
  9. 9.
    Milne GWA, ed: Traditional Chinese Medicines: Molecular Structures, Natural Sources and Applications. Aldershot, UK: Ashgate Press; 2001.Google Scholar
  10. 10.
    Williamson EM: Review. Synergy and other interactions in phytomedicines. Phytomedicine 2001, 8:410–409.CrossRefGoogle Scholar
  11. 11.
    Lieber CS, Leo MA, Cao Q, et al.: Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003, 37:336–339. This study offers a possible explanation as to why the excellent results achieved with silymarin in alcohol-related animal studies in particular may be hard to emulate in human studies.PubMedCrossRefGoogle Scholar
  12. 12.
    Sakaida I, Matsumara Y, Akiyama S, et al.: Herbal medicine, Sho-saiko-to (TJ-9) prevents liver fibrosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 1998, 29:642–649.PubMedCrossRefGoogle Scholar
  13. 13.
    Li YM, Ryan P, Batey RG: Traditional Chinese medicine prevents inflammation in CCl.4-related liver injury in mice. Am J Chinese Med 2003, 31:119–127.CrossRefGoogle Scholar
  14. 14.
    Hewawasam RP, Jayatilaka KA, Pathirana C, Mudduwa LK: Hepatoprotective effects of Epaltes divaricata extract on carbon tetrachloride induced hepatotoxicity in rats. Indian J Med Res 2004, 10:1037–1042.Google Scholar
  15. 15.
    Luo YJ, Uyu JP, Shi ZH, Wang L: Ginkgo biloba extract reverses CCl4-induced liver fibrosis in rats. World J Gastroenterol 2004, 10:1037–1042.PubMedGoogle Scholar
  16. 16.
    Lee TY, Mai LM, Wang GJ, et al.: Protective mechanism of Salvia miltiorrhiza on carbon tetrachloride induced acute hepatotoxicity in rats. J Pharmacol Sci 2003, 91:202–211.PubMedCrossRefGoogle Scholar
  17. 17.
    Muriel P, Moreno MG: Effects of silymarin and vitamins E and C on liver damage induced by prolonged biliary obstruction in the rat. Basic Clin Pharmacol Toxicol 2004, 94:99–104.PubMedGoogle Scholar
  18. 18.
    Flora K, Hahn M, Rosen H, Benner K: Milk thistle for the therapy of liver disease Am J Gastroenterol 1998, 93:139–143.PubMedCrossRefGoogle Scholar
  19. 19.
    Van Rossum TG, Vulto AG, De Man RA, et al.: Review article: Glycyrrhizin as a potential treatment for chronic hepatitis C. Alimentary Pharmacol Ther 1998,12:199–205.CrossRefGoogle Scholar
  20. 20.
    Chang IM: Antiviral activities of aucubin against hepatitis B virus replication. Phyto Res 1997,11:189–192.CrossRefGoogle Scholar
  21. 21.
    Jeong HJ, Koo HN, Na HJ et al.: Inhibition of TNF-alpha and IL-6 production by aucubin through blockade of NF-kappaB activation RBL-2H3 mast cells. Cytokine 2002, 18:252–259. A valuable paper demonstrating the capacity of aucubin to modulate tumor necrosis factor (TNF)-’a and interleukin (IL)-6 production in mast cells via inhibition of NFêB activation. Although it does not study liver disease directly, the work points to possible mechanisms of action of other alternative medicines and should serve as a template for future experiments.PubMedCrossRefGoogle Scholar
  22. 22.
    Ott M, Thayagarajan SP, Gupta S: Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer I and cellular transcription factors. Eur J Clin Invest 1997, 27:908–915.PubMedCrossRefGoogle Scholar
  23. 23.
    Oka H, Yamamoto S, Kuroki T, et al.: Prospective study of chemoprevention of hepatocellular carcinoma with Shosaiko- to (TJ-9) Cancer 1995, 76:743–749.PubMedCrossRefGoogle Scholar
  24. 24.
    Rietveld A, Wiseman S: Antioxidant effects of tea: evidence from human clinical trials. J Nutr 2003, 133:3285S-3292S.PubMedGoogle Scholar
  25. 25.
    Center SA: Metabolic antioxidant, nutraceutical, probiotic and herbal therapies relating to the management of hepatobiliary disorders. Vet Clin North Am Small Anim Pract 2004, 34:67–172.PubMedCrossRefGoogle Scholar
  26. 26.
    Lucena MI, Andrale RJ, de la Cruz JP, et al.: Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Int J Clin Pharmacol Ther 2002, 40:2–8.PubMedGoogle Scholar
  27. 27.
    Kim NC, Graf TN, Sparacino CM, et al.: Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Organic Biomol Chem 2003, 1:1648–1649.Google Scholar
  28. 28.
    Saller R, Meier R, Brignoli R: The use of silymarin in the treatment of liver diseases. Drugs 2001, 61:2035–2063.PubMedCrossRefGoogle Scholar
  29. 29.
    Jacobs BP, Dennehy C, Ramirez G, et al.: Review: Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med 2002, 113:506–515.PubMedCrossRefGoogle Scholar
  30. 30.
    Ferenci P, Dragosics B, Dittrich H, et al.: Randomised controlled trial of silymarin treatment in patients with cirrhosis of the liver. J. Hepatol 1989, 9:105–113.PubMedCrossRefGoogle Scholar
  31. 31.
    Kumada H: Long term treatment of chronic hepatitis C with glycyrrhizin [Stronger Neo-Minophagen C (SNMC) for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 2002, 62(Suppl 1):94–100.PubMedCrossRefGoogle Scholar
  32. 32.
    Martin KW, Ernst E: Review: Antiviral agents from plants and herbs: a systematic review. Antiviral Ther 2003, 8:77–90.Google Scholar
  33. 33.
    Harrison SA, Torgerson S, Hayashi P, et al.: Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98:2486–2490.Google Scholar
  34. 34.
    Yang H, Sadda MR, Li M, et al.: S-adenosylmethionine and its metabolite induce apoptosis in HepG2 cells: role of protein phosphatase 1 and Bcl-xs. Hepatology 2004, 40:221–231.PubMedCrossRefGoogle Scholar
  35. 35.
    De Silva HA, Saparamadu PAM, Thabrew MI, et al.: Liv.52 in alcoholic liver disease: a prospective, controlled trial. J Ethnopharmacol 2003, 84:47–50.CrossRefGoogle Scholar
  36. 36.
    Fan JG: Shanghai Multicentre Clinical Cooperative Group Of Danning Pian Trial: Evaluating the efficacy and safety of Danning Pian in the short term treatment of patients with non-alcohol fatty liver disease, a multicenter trial. Hepatobiliary Pancreat Dis Int 2004, 3:375–380.PubMedGoogle Scholar
  37. 37.
    Liu JP, McIntosh H, Lin H. Chinese medicinal herbs for hepatitis B: a systematic review. Liver Int 2001, 21:280–286.CrossRefGoogle Scholar
  38. 38.
    Liu JP, Manheimer E, Tsutani K, Gludd C: Medicinal herbs for hepatitis C infection. Cochrane Database System Rev 2001, 4:CD003183.Google Scholar
  39. 39.
    Mabed M, El-Helw L, Shamaa S: Phase II study of Viscum fraxini-2 in patients with advanced hepatocellular carcinoma. Br J Cancer 2004, 90:65–69.PubMedCrossRefGoogle Scholar
  40. 40.
    Stickel F, Brinkhaus B, Krahmer N, et al.: Antifibrotic properties of botanicals in chronic liver disease. Hepato-Gastroenterology 2002, 49:1102–1108.PubMedGoogle Scholar
  41. 41.
    Wang B-E. Management of chronic hepatitis B: treatment of chronic liver disease with traditional Chinese medicine. J Gastroenterol Hepatol 2000, 15(Suppl):E67-E70.PubMedCrossRefGoogle Scholar
  42. 42.
    Chan HL, Sung JJ, Fong WF, et al.: Double-blind placebo controlled study of Phyllanthus urinaris for treatment of chronic hepatitis B. Aliment Pharmacol Ther 2003, 18:339–345.PubMedCrossRefGoogle Scholar
  43. 43.
    Li W, Wang C, Zhang J: Effects of Da Ding Feng Zhu decoction in 30 cases of liver fibrosis. J Trad Chinese Med 2003, 23:251–254.Google Scholar
  44. 44.
    Gao ZL, Gu XH, Cheng FT, Jiang FH: Effect of sea buckthorn on liver fibrosis: a clinical study. World J Gastroenterol 2003, 9:1615–1617.PubMedGoogle Scholar
  45. 45.
    Jakkula M, Boucher TA, Beyendorff U, et al.: A randomized trial of Chinese herbal medicines for the treatment of symptomatic hepatitis C. Arch Intern Med 2004, 164:1341–1346.PubMedCrossRefGoogle Scholar
  46. 46.
    Gunawan B, Kaplowitz N: Clinical perspectives on xenobioticinduced hepatoxicity. Drug Metab Rev 2004, 36:301–312.PubMedCrossRefGoogle Scholar
  47. 47.
    Stewart MJ, Steenkamp V: Pyrrolizidine poisoning: a neglected area in human toxicology. Ther Drug Monit 2001, 23:698–708.PubMedCrossRefGoogle Scholar
  48. 48.
    Pittler MH, Ernst E: Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 2003, 18:451–471. This paper provides the laboratory, histologic, and clinical data related to cases of reported hepatotoxicity. The authors meticulously list concurrent medications alongside the reported hepatotoxic agent, which is relevant in judging probability of the herbal agent alone causing the hepatotoxicity.PubMedCrossRefGoogle Scholar
  49. 49.
    Schiano TD: Hepatotoxicity and complementary and alternative medicines. Clin Liver Dis 2003, 7:453–473.PubMedCrossRefGoogle Scholar
  50. 50.
    Stedman C: Herbal hepatotoxicity. Semin Liver Dis 2002, 22:195–206.PubMedCrossRefGoogle Scholar
  51. 51.
    Anke J, Ramzan I: Kava hepatotoxicity: Are we any closer to the truth? Planta Med 2004, 70:193–196.PubMedCrossRefGoogle Scholar
  52. 52.
    Whiting PW, Clouston A, Kerlin P: Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust 2002, 177:440–443.PubMedGoogle Scholar
  53. 53.
    Thomsen M, Schmidt M: Hepatotoxicity from Cimicifuga racemosa? Recent Australian case report insufficiently substantiated. J Alt Complement Med 2003, 9:337–340.CrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2005

Authors and Affiliations

  • Robert G. Batey
    • 1
  • Ses J. Salmond
    • 1
  • Alan Bensoussan
    • 1
  1. 1.Faculty of HealthUniversity of Newcastle, AustraliaWallsendAustralia

Personalised recommendations